Tenaya Therapeutics to Participate in Upcoming October Investor Conferences
Tenaya Therapeutics (NASDAQ: TNYA) announced CEO Faraz Ali will participate in investor and industry conferences in October 2025. Key events: Cell & Gene Meeting on the Mesa on October 6 with a panel at 8:00–9:00 AM MT and a company presentation at 12:00–12:15 PM MT; and the Chardan Annual Genetic Medicines Conference on October 21 with a panel 12:00–12:40 PM ET titled "In Vivo Gene Therapies for Genetic Cardiac Diseases."
The Chardan panel will be webcast live and an archived replay will be available on Tenaya's investor website for ~30 days.
Tenaya Therapeutics (NASDAQ: TNYA) ha annunciato che il CEO Faraz Ali parteciperà a conferenze per investitori e per l’industria nell’ottobre 2025. Eventi chiave: Cell & Gene Meeting on the Mesa il 6 ottobre con un panel 8:00–9:00 AM MT e una presentazione aziendale 12:00–12:15 PM MT; e la Chardan Annual Genetic Medicines Conference il 21 ottobre con un panel 12:00–12:40 PM ET intitolato "In Vivo Gene Therapies for Genetic Cardiac Diseases."
Il panel Chardan sarà trasmesso in diretta web e una versione archiviata sarà disponibile sul sito degli investitori di Tenaya per circa 30 giorni.
Tenaya Therapeutics (NASDAQ: TNYA) anunció que el CEO Faraz Ali participará en conferencias para inversionistas y la industria en octubre de 2025. Eventos clave: Cell & Gene Meeting on the Mesa el 6 de octubre con un panel de 8:00 a 9:00 a. m. MT y una presentación de la empresa de 12:00 a 12:15 p. m. MT; y la Chardan Annual Genetic Medicines Conference el 21 de octubre con un panel de 12:00 a 12:40 p. m. ET titulado "In Vivo Gene Therapies for Genetic Cardiac Diseases."
El panel de Chardan se transmitirá en vivo por la web y se podrá ver una reproducción archivada en el sitio de inversores de Tenaya durante unos 30 días.
Tenaya Therapeutics (NASDAQ: TNYA)의 CEO Faraz Ali가 2025년 10월에 투자자 및 업계 회의에 참석할 것임을 발표했습니다. 주요 행사: Cell & Gene Meeting on the Mesa가 10월 6일 MT 기준 오전 8:00–9:00 패널 및 회사 발표 12:00–12:15 사이; 그리고 Chardan Annual Genetic Medicines Conference가 10월 21일 12:00–12:40 PM ET 패널로 열리며 제목은 "In Vivo Gene Therapies for Genetic Cardiac Diseases."
Chardan 패널은 실시간으로 방송되며 Tenaya의 투자자 웹사이트에서 약 30일간 보관 재생을 볼 수 있습니다.
Tenaya Therapeutics (NASDAQ : TNYA) a annoncé que le PDG Faraz Ali participera à des conférences pour investisseurs et l’industrie en octobre 2025. Évènements clés : Cell & Gene Meeting on the Mesa le 6 octobre avec un panel de 8:00 à 9:00 MT et une présentation de l’entreprise de 12:00 à 12:15 MT ; et la Chardan Annual Genetic Medicines Conference le 21 octobre avec un panel de 12:00 à 12:40 PM ET intitué "In Vivo Gene Therapies for Genetic Cardiac Diseases."
Le panel Chardan sera diffusé en direct et une rediffusion archivée sera disponible sur le site des investisseurs de Tenaya pendant environ 30 jours.
Tenaya Therapeutics (NASDAQ: TNYA) gab bekannt, dass CEO Faraz Ali an Investoren- und Branchenkonferenzen im Oktober 2025 teilnehmen wird. Wichtige Veranstaltungen: Cell & Gene Meeting on the Mesa am 6. Oktober mit einem Panel von 8:00–9:00 Uhr MT und einer Unternehmenspräsentation von 12:00–12:15 Uhr MT; und die Chardan Annual Genetic Medicines Conference am 21. Oktober mit einem Panel von 12:00–12:40 Uhr ET mit dem Titel "In Vivo Gene Therapies for Genetic Cardiac Diseases."
Das Chardan-Panel wird live gestreamt, und eine archivierte Wiedergabe wird auf der Investorenwebseite von Tenaya für ca. 30 Tage verfügbar sein.
Tenaya Therapeutics (Nasdaq: TNYA) أعلنت أن الرئيس التنفيذي فراز علي سيشارك في مؤتمرات للمستثمرين والصناعة في أكتوبر 2025. الأحداث الرئيسية: Cell & Gene Meeting on the Mesa في 6 أكتوبر مع لوحة من 8:00 إلى 9:00 صباحاً بتوقيت MT وجلسة عرض للشركة من 12:00 إلى 12:15 مساءً بتوقيت MT؛ وChardan Annual Genetic Medicines Conference في 21 أكتوبر مع لوحة من 12:00 إلى 12:40 مساءً بتوقيت ET بعنوان "In Vivo Gene Therapies for Genetic Cardiac Diseases."
سيتم بث جلسة تشاردان مباشرة وستتوفر إعادة عرض أرشيفية على موقع المستثمرين الخاص بتينايا لمدة نحو 30 يوماً.
Tenaya Therapeutics (NASDAQ: TNYA) 宣布首席执行官 Faraz Ali 将参加 2025 年 10 月的投资者和行业会议。关键活动：Cell & Gene Meeting on the Mesa 将于 10 月 6 日举行，MT 时区上午 8:00–9:00 的小组讨论以及公司介绍 12:00–12:15；Chardan Annual Genetic Medicines Conference 将于 10 月 21 日举行，12:00–12:40 PM ET 的小组讨论，题为 "In Vivo Gene Therapies for Genetic Cardiac Diseases。"
Chardan 小组讨论将实时网络直播，Tenaya 的投资者网站将提供约 30 天的存档回放。
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the following October investor and industry conferences. Details are below:
Cell & Gene Meeting on the Mesa
Date: Monday, October 6
Time: 8:00 AM MT – 9:00 AM MT
Format: Panel Discussion
Title: Future Horizons: Emerging Trends and Opportunities in Cell and Gene Therapy Development
Date: Monday, October 6
Time: 12:00 PM MT – 12:15 PM MT
Format: Company Presentation
Chardan Annual Genetic Medicines Conference
Date: Tuesday, October 21
Time: 12:00 PM ET – 12:40 PM ET
Format: Panel Discussion
Title: In Vivo Gene Therapies for Genetic Cardiac Diseases
The live webcast of the In Vivo Gene Therapies for Genetic Cardiac Diseases Panel Discussion may be accessed from the Investors section of Tenaya’s website. An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
FAQ
When will Tenaya Therapeutics (TNYA) present at the Cell & Gene Meeting on the Mesa in October 2025?
What time is Tenaya's panel at the Chardan Annual Genetic Medicines Conference (TNYA) on Oct 21, 2025?
Who from Tenaya (TNYA) is speaking at the October 2025 conferences?
How can investors watch Tenaya's (TNYA) Chardan conference panel webcast?
Will Tenaya's (TNYA) conference webcast be available after the event?
What topics will Tenaya (TNYA) cover at the October 2025 conferences?
